1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

Pink Sheet Podcast Special: Assessing US FDA Commissioner Robert Califf’s First 100 Days

Editors from the Pink Sheet and sister publications covering the medical device and health, beauty and wellness sectors look at Califf’s goals, accomplishments and trials during the early days of his second term.

Pink Sheet podcast
HOW WILL CRISES IN THE FDA'S FOOD PROGRAM AFFECT CALIFF'S GOALS FOR THE DRUG, BIOLOGICS AND DEVICE CENTERS? • Source: Pink Sheet illustration

Reporters and editors from the Pink Sheet, MedTech Insight and HBW Insight discuss the first 100 days of US Food and Drug Administration Commissioner Robert Califf’s second stint as FDA Commissioner, including goals, accomplishments, trials and tribulations across the drug, device and health and wellness sectors and how ongoing crises like the infant formula shortage could affect them. They also consider the potential for lasting change at the agency going forward.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA Extracts More Evidence To Ban Kratom

 
• By Malcolm Spicer

Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.

Cloudy Tariff Conditions Expected To Linger In US

 
• By Malcolm Spicer

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA Has Lists To Assure Progress On Supplement Sector Regulations, NDIN Guidance

 
• By Malcolm Spicer

The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful

More from Policy & Regulation

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

Cloudy Tariff Conditions Expected To Linger In US

 
• By Malcolm Spicer

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.